.png)
Consumers who paid any amount of money for retail purchases of Valsartan medication manufactured by Hetero and distributed by Camber Pharmaceuticals between May 1, 2018, and July 31, 2018, may be eligible to claim a cash payment from a class action settlement.
Hetero Drugs Ltd., Hetero Labs Ltd., Hetero USA Inc. and Camber Pharmaceuticals Inc. agreed to pay $11,365,489.80 to resolve a class action lawsuit. The lawsuit alleged Hetero manufactured, distributed, sold or dispensed Valsartan or Valsartan-containing drugs contaminated with probable human carcinogens, specifically N-nitrosodimethylamine, resulting in economic losses for consumers.
The settlement is part of a larger multidistrict litigation, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation. There is also a $2,000,000 Aurobindo Irbesartan settlement.
Who can file a claim?
Class members must meet all of the following criteria:
- They are an individual in the United States, its territories or possessions.
- They paid any amount of money for retail purchases of Valsartan finished drug formulations that used the Hetero Process III Valsartan active pharmaceutical ingredient.
- They made the purchase between May 1, 2018, and July 31, 2018.
Class members can check the National Drug Code on their prescription bottle or pharmacy records to determine if their medication qualifies. Qualifying prescriptions may include National Drug Codes 31722-747-90 (160mg) and 31722-748-90 (320mg).
Pharmacy benefit managers do not qualify for this settlement.
How much can class members receive?
The settlement provides compensation based on the amount of qualifying Hetero Valsartan the class member purchased. The standard award is up to $40 for each 30-day supply purchased with a maximum of $120 per consumer.
However, those who provide documentation (such as receipts or pharmacy records) showing they paid more than $40 for a 30-day supply may be eligible to receive a payment above the $40 per 30-day supply and $120 total cap.
There is no cap for documented claims above the standard amount; however, the settlement caps total payments to consumers at 40% of the net settlement fund after deductions for attorneys’ fees, expenses, administration costs and service awards. If the total of all valid claims exceeds this cap, the settlement administrator will reduce payments proportionally.
How to claim a class action payment
Class members can file a claim online or download and print a PDF claim form to mail to the settlement administrator. The deadline to submit a claim is June 2, 2026.
Settlement administrator's mailing address: Hetero Settlement Administrator, PO Box 3376, Baton Rouge, LA 70821
The settlement website does not specify payment options.
What proof or documentation is required to submit a claim?
- For claims up to $40 per 30-day supply and $120 total, class members do not need to submit documentation. However, the settlement administrator may request proof to verify claims.
- For claims above $40 per 30-day supply or above $120 total, class members must submit documentation, such as pharmacy receipts or records.
$11.37 million settlement fund breakdown
The $11,365,489.80 settlement fund covers:
- Settlement administration costs: To be determined
- Attorneys' fees: Up to $3,788,496.60
- Attorneys' expenses: To be determined
- Service awards to class representatives: $5,000 for each of the five consumer class representatives and $15,000.00 for each of the two TPP representative plaintiffs ($55,000 total)
- Payments to class members: Remaining funds
Important dates
- Deadline to file a claim: June 2, 2026
- Exclusion deadline: June 2, 2026
- Fairness hearing: June 30, 2026
When is the Hetero Valsartan settlement payout date?
The settlement administrator will distribute payments to eligible class members after it completes claim processing and the court grants final approval of the settlement.
Why is there a class action settlement?
The settlement alleged the Hetero defendants violated state laws by manufacturing, distributing and selling Valsartan or Valsartan-containing drugs contaminated with NDMA, a probable human carcinogen. The lawsuit claimed this contamination caused economic losses to consumers.
The defendants deny any wrongdoing or liability but agreed to settle to avoid the cost and uncertainty of further litigation.
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
.svg)